Performance/Muscle

MGF

Research Reagent · Laboratory Use Only

Quick Answer

What is the difference between MGF and PEG-MGF in muscle research?

MGF (Mechano Growth Factor) is a naturally occurring splice variant of IGF-1 produced by muscle in response to mechanical loading, with a half-life of minutes. PEG-MGF is the polyethylene glycol-conjugated synthetic form engineered for extended half-life. Native MGF acts as a local autocrine/paracrine signal for satellite cell activation; PEG-MGF is used for sustained-release research models.

PMID12055211↗DOI10.1113/jphysiol.2002.018424↗⟳ Reconstitution Calculator
Scientific AbstractPMID 12055211 · 2002

Mechano Growth Factor (MGF) is a splice variant of the insulin-like growth factor 1 (IGF-1) gene produced by skeletal muscle in response to mechanical stretch, eccentric exercise, or injury. Unlike systemic IGF-1, MGF acts locally at the site of muscle damage to activate satellite cells, the muscle stem cell population responsible for fiber repair and hypertrophy. The peptide has a short half-life (minutes) and is distinct from PEG-MGF, the polyethylene glycol-conjugated form engineered to extend half-life for sustained release. Native MGF research focuses on its role as a local autocrine/paracrine signal in exercise-induced muscle adaptation.

Source:10.1113/jphysiol.2002.018424
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is MGF?

Mechano Growth Factor (MGF) is a splice variant of IGF-1 produced by skeletal muscle in response to mechanical loading or injury. It acts locally as an autocrine/paracrine signal to activate satellite cells for muscle fiber repair and hypertrophy.

Mechanism of Action

Mechanical stretch triggers alternative splicing of the IGF-1 gene to produce MGF, which activates muscle satellite cells (the muscle stem cell population) for fusion with damaged fibers and hypertrophic adaptation. MGF has a short half-life of minutes, distinguishing it from PEG-MGF.

Observed Laboratory Results

  • Satellite cell activation at sites of mechanical loading or damage
  • Short half-life of minutes versus hours for PEG-MGF
  • Local autocrine/paracrine action versus systemic IGF-1
  • Induction by eccentric exercise in human muscle biopsy studies

Comparison to PEG-MGF

The PEG-MGF variant adds polyethylene glycol to extend half-life and enable sustained-release research, while native MGF preserves the natural pulsatile, locally restricted signal.

Clinical Research ParametersHuman Study Registry

No registered clinical trials or indexed human study data currently available for MGF via ClinicalTrials.gov or PubMed. This compound may be at preclinical or early research stages.

Search ClinicalTrials.gov ↗Search PubMed ↗
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. MGF is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 12055211) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Performance/Muscle Research Compounds

IGF-1 LR3
INTRODUCTION: Volumetric muscle loss (VML) resulting from severe extremity injuries in com…
→
DES(1-3) IGF-1
BACKGROUND: Although oral squamous cell carcinomas (OSCCs) commonly overexpress the epider…
→
PEG-MGF
Molecular granular materials (MGMs) assembled from subnanometer clusters exhibit unique vi…
→
Follistatin 344
PURPOSE: To present 11 bodybuilding athletes who developed central serous chorioretinopath…
→
View all Performance/Muscle compounds →